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Abstract 
Background: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-
oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, 
consisting mainly of small case series and reports.
Methods: A retrospective database was used to identify consecutive patients diagnosed with aggressive fibroma-
tosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre 
between 2007 and 2014. MRI and symptom changes were recorded.
Results: Thirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment 
with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced wors-
ening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable 
disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. 
One patient achieved a partial response with improved symptoms.
Conclusions: No relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Pro-
spective studies in AF should incorporate endpoints focusing on patient symptoms.
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Background
Aggressive fibromatosis (AF), also named desmoid-type 
fibromatosis, is characterised by monoclonal myofibro-
blastic proliferation in soft tissues. It is a rare disease 
accounting for 3% of all soft tissue neoplasms, with an 
incidence of 2–5 people per million per year [1]. It has 
a female predominance and a peak incidence in the 
third to fourth decades [2]. AF is often sporadic, how-
ever, there is a reported increased incidence of 3.5–32% 
in patients with familial adenomatous polyposis (FAP) 
or Gardner’s variant [3, 4]. AF is usually solitary but 
multifocal tumours have been reported [5]. It may arise 
from any anatomical site, commonly the extremities, 
abdominal and chest wall and paravertebral tissues [6, 7]. 
Although AF is slow growing without metastatic poten-
tial, its unpredictable behaviour, propensity for pro-
gressive infiltration and local invasion makes treatment 
challenging. Currently there is no established evidence-
based approach to treatment [8], although a consensus 
approach based on wide consultation with physicians 
and patient groups has been published [9]. Active surveil-
lance is now often used in asymptomatic cases [10]. High 
local recurrence rates of 15–50% [11–14] up to 87% [15] 
in younger patients, despite apparently complete resec-
tion, have reduced the popularity of surgical resection as 
initial management. Radiotherapy can help improve local 
control [16] however, side effects, including radiation-
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Drugs used in the treatment of AF, include hormonal 
therapy (e.g. tamoxifen and toremifene) [18], Non ste-
roidal antinflammatory drugs (NSAIDs) and cytotoxic 
chemotherapeutic agents, such as anthracycline-based 
regimens [19] (including pegylated liposomal doxoru-
bicin [20]) and vinblastine plus methotrexate [21]. Tyros-
ine kinase inhibitors, including imatinib [22], sorafenib 
[23] and pazopanib [24] can also play a role in the treat-
ment of AF. A recent phase I study demonstrated dem-
onstrated promising efficacy of a γ-secretase inhibitor in 
desmoid tumours [25].
For many centres, first line systemic treatment of non-
resectable or symptomatic desmoid-type fibromatosis 
consists of hormonal manipulation, with or without a 
NSAID. Particularly in centres within the United King-
dom, this is heavily influenced by lack of reimbursed 
alternatives, availability and the low side effect profile. 
Immunohistochemical studies have demonstrated the 
presence of oestrogen receptor-beta in 90% of desmoid-
type tumours [26]. This is supported by the tendency of 
fibromatosis to occur more often in women, particularly 
during pregnancy/within 1 year post partum [27], or on 
oral contraception, and there are reports of spontane-
ous regression during menopause and post-partum [2, 
28]. Several publications have documented the effective-
ness of hormonal manipulation in AF treatment [29–32]. 
Despite the lack of randomised prospective data, it has 
been reported that antioestrogen therapy can be effec-
tive in about half of patients [18]. Tamoxifen is a non-
steroidal triphenylethylene derivative that binds to 
oestrogen receptors. One suggested mechanism for the 
anti-proliferative action of tamoxifen is regulation of the 
synthesis of the cytokine transforming growth factor-β 
(TGF-β) [32] and its receptors, which are also involved in 
AF pathogenesis.
There are several means of monitoring treatment 
response, including clinical evaluation of tumour size and 
symptoms as well as radiological. The Response Evalu-
ation Criteria in Solid Tumours (RECIST 1.1) [33] are 
currently employed within clinical trials. Magnetic reso-
nance imaging (MRI) has become the imaging modality 
of choice for soft tissue lesions, due to better evaluation 
of the tumour and its relationship with surrounding 
structures such as nerves and vessels. Given the chronic 
nature of the disease, the lack of radiation exposure 
makes MRI ideal for follow up studies. Furthermore, in 
lesions undergoing radiation or drug therapy, MR sur-
veillance has been used to assess response to treatment 
with a decrease in T2-weighted signal and lesion size 
being suggested as indicators of treatment response [34].
The variable content of spindle cells, collagen and myx-
oid tissue of AF correlates with the observation that these 
lesions often show heterogeneous signals on MRI [35]. In 
particular, the highly cellular, actively growing lesions tend 
to be of high signal on T2-weighted MR images [6, 36, 37]. 
Interspersed low signal bands correspond with the colla-
gen bundles. As the lesion matures, the increase in collagen 
deposition and decreased cellularity result in a decrease in 
T2 signal [38, 39]. However to date it has not been possible 
to predict behaviour based on MRI signal [40, 41].
The main aims of this study were to assess MRI 
response and symptom control in patients with AF 
treated with tamoxifen with or without NSAIDs.
Methods
Patient selection
The prospectively collected Royal Marsden Hospital sar-
coma database was used to identify consecutive patients 
diagnosed with AF and treated with tamoxifen at our ter-
tiary referral centre between 2007 and 2014. Institutional 
approval was obtained. Inclusion criteria were patients 
aged 18 years and over, treated with tamoxifen, with a base-
line and at least one follow-up MRI scan. Demographic 
data, disease characteristics, previous treatments, date of 
starting and stopping tamoxifen, toxicity and clinical symp-
toms were collected from clinical notes. Descriptive statis-
tical analysis was applied: progression-free survival (PFS) 
was calculated using the Kaplan–Meier method.
Imaging data
Baseline MRI images, defined as the last MRI performed 
prior to tamoxifen treatment, and subsequent follow 
up MRI images were identified for each patient. Where 
available a pre-baseline MRI was also collected. On aver-
age 3 (range 2–6) follow up MRIs were assessed for each 
patient. The minimum MRI protocol for inclusion in the 
study was axial T1W, T2W, STIR and coronal T2W and 
STIR images. All images were re-reviewed by a special-
ist soft tissue radiologist (CM). Tumour size, RECIST 1.1 
assessment and T2-weighted signal changes were docu-
mented at each time point.
Results
Between 2007 and 2014 a total of 35 patients were treated 
with tamoxifen at the Royal Marsden Hospital. Baseline 
imaging was not available for 3 patients, and they were 
therefore not eligible for this study. Of the remaining 32 
cases, the median age at the time of commencing tamox-
ifen was 41  years (range 19–68  years). There was a 3:2 
female to male ratio [19 (60%): 13 (40%)]. One patient 
(3%) had a diagnosis of FAP. The most common site of 
origin was limb and limb girdle (18; 56%), followed by 
chest wall (5; 15%), pelvis (3; 10%), abdominal wall (3; 
10%), paravertebral tissues (1; 3%) and head/neck (2; 6%).
Fourteen patients (44%) received tamoxifen as first-line 
treatment. Eighteen of 32 patients (56%) had been treated 
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previously, with surgery, radiotherapy, steroid injections, 
NSAIDs or doxorubicin chemotherapy. Patient and dis-
ease characteristics are summarised in Table 1.
Tamoxifen treatment was started due to tumour 
growth and worsening symptoms, mostly characterised 
by pain, including neuropathic and somatic pain, and 
decreased range of movement. Four patients (12%) were 
asymptomatic at the time of starting tamoxifen.
The average length of time on tamoxifen was 316 days, 
ranging from 1 month to 3 years (33–997 days). Tamox-
ifen dosages used were 40  mg (15 patients), 20  mg (15 
patients), 10  mg (1 patient) and unknown (1 patient). 
Twenty-four patients (75%) received tamoxifen in asso-
ciation with a NSAID (naproxen or diclofenac). Thirteen 
of the 32 patients (41%) suffered from tamoxifen-related 
side effects, most commonly hot flushes and mood 
swings. Two patients had their 40  mg dose reduced to 
20 mg due to side effects. One of those was a 40-year old 
male who experienced increased tiredness and the other 
a 27-year old male who suffered from mood swings, 
fatigue and hot flushes.
The most common reasons for stopping tamoxifen were 
tumour progression (10, 31%), and grade 2–3 side effects 
(8, 25%), such as hot flushes, mood swings and fatigue. 
Four patients (13%) stopped due to lack of any perceived 
benefit and 3 (9%) due to worsening symptoms. One 
patient with stable disease stopped tamoxifen as she was 
planning on starting a family and she was aware of pos-
sible associated birth defects [42]. One patient stopped 
tamoxifen because of pregnancy. Two patients died for 
reasons unrelated to AF. One patient stopped tamoxifen 
due to side effects, and subsequently received an anti-
tumour necrosis factor (anti-TNF)-α agent, adalimumab 
[43], for his rheumatoid arthritis and the AF decreased in 
size. Two patients continue on tamoxifen.
Tamoxifen with or without a NSAID, resulted in symp-
tom improvement in 10 patients (31%)—5 patients on 
40  mg tamoxifen, 4 patients on 20  mg tamoxifen and 1 
patient on 10 mg tamoxifen (8 of these 10 patients were 
also taking NSAIDs). Worsening symptoms were experi-
enced by 9 patients (28%)—2 patients on 40 mg tamox-
ifen, 6 patients on 20  mg tamoxifen and 1 unknown (6 
of these 9 patients were also taking NSAIDs). Thirteen 
patients did not experience any change in symptoms 
(41%)—9 patients on 40  mg tamoxifen, 4 patients on 
20 mg tamoxifen (10 of these 13 patients were also tak-
ing NSAIDs). The majority of patients with symptomatic 
benefit did not have significant changes in size or signal 
on MRI (Fig. 1a, b).
The median tumour size on starting tamoxifen was 
60 mm (range 23–165 mm). There was a varied response 
in tumour size. Eighteen patients (56%) had increase in 
tumour size, 6 patients (19%) had a reduction in tumour 
size and 8 patients (25%) had no change in tumour size. 
By RECIST 1.1, 9 patients (28%) had progressive dis-
ease—6 patients on 40 mg tamoxifen, 2 patients on 20 mg 
tamoxifen and 1 unknown; 22 patients (69%) had stable 
disease—8 patients on 40  mg tamoxifen, 13 patients on 
20  mg tamoxifen, 1 patient on 10  mg tamoxifen and 1 
patient (3%) had a partial response—40  mg tamoxifen. 
Median progression-free survival (PFS) per RECIST 
1.1 was 10  months with (95% CI 6.4–24.6); PFS at 1 
and 2  years was 50% (95% CI 32–66) and 34% (95% CI 
19–51), respectively (Fig. 2), with a median follow-up of 
45.5 months (range 14–105).
We divided our series into three RECIST 1.1 criteria-
based groups: progressive disease, stable disease and 
partial response. Of 9 patients with progressive disease 
(28%): 4 patients experienced worsening symptoms with 
increased pain; 3 patients had an improvement in pain 
and increase in range of movement and no change in 
symptoms was observed in the remaining 2 patients. T2 
signal increase was observed in 1 case, which correlated 
with clinical deterioration; in 8 of 9 cases there was no 
change in T2 signal. Of 22 patients with stable disease 
(69%): 11 had no change in symptoms with T2 signal 
reduction in 3 cases and increase in 1; 6 experienced 
symptom improvement: 1 of 6 had a correlating T2 signal 
reduction. Five patients complained of worsening symp-
toms without any change in T2 signal.
One patient achieved a partial response (3%). This 
patient was a 35-year old male affected by AF involving 
Table 1 Patient and disease characteristics
# (%) [range]
Number of patients 32
 Male 14 (40%)
 Female 19 (60%)
Median age on starting tamoxifen 41 [19–68]
Site of origin
 Extremities (including girdle) 18 (56%)
 Chest wall 5 (15%)
 Pelvis 3 (10%)
 Abdominal wall 3 (10%)
 Paravertebral 1 (3%)
 Head and neck 2 (6%)
Sporadic disease 31 (97%)
FAP-associated 1 (3%)
Previous treatments 18 (56%)
 Local treatment
  Surgery 10 (31%)
  Surgery and RT 7 (21%)
  RT alone 0
 Systemic treatment 4 (12%)
No previous treatment 14 (44%)
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the right anterior abdominal wall with abdominal pain at 
baseline. This patient is still on treatment, and has com-
pleted 476 days of therapy at the time of analysis. After 
18 months of treatment, he experienced an improvement 
in symptoms with a reduction in pain. The symptomatic 
improvement corresponded with a decrease in size and 
T2 signal on MRI (Fig. 3).
Additional pre-baseline MRI scans were available for 
14 patients. Thirteen out of 14 patients’ tumours were 
increasing in size prior to starting tamoxifen. Six con-
tinued to increase following tamoxifen; 5 showed some 
decrease in size; 2 became stable having demonstrated 
growth prior to starting tamoxifen.
Discussion
Aggressive fibromatosis is a challenging disease with an 
unpredictable behaviour. The unsatisfactory outcomes 
of surgery and the fact that growth arrest and regression 
can occur spontaneously have led to the increased adop-
tion of active surveillance as the initial approach to man-
agement [44]. However hormonal manipulation has been 
commonly used particularly in the United Kingdom as 
first-line systemic therapy in AF [10].
Our study of 32 patients is limited by the retrospec-
tive design and the collection of symptomatic changes by 
Fig. 1 Barcharts of patient symptoms and corresponding RECIST 1.1 status (a) and T2W MRI signal changes (b)
Fig. 2 Kaplan–Meier progression free survival analysis after treatment 
with tamoxifen. Median PFS was 10 months (95% CI 6.4–24.6)
Fig. 3 Axial T2 weighted MRI images showing right anterior abdominal wall fibromatosis in a 35-year old male (a) and the corresponding MRI after 
7 months of treatment with tamoxifen (b) show decrease in size and T2 signal
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retrospective case note review rather than prospective 
dedicated questionnaires. However, to our knowledge, 
this is the largest single series evaluating the relationship 
between symptoms and MRI response in patients with 
AF treated with tamoxifen with/without NSAIDs.
Within this case series, 14 of the 32 patients (44%) 
received tamoxifen as first-line treatment. This could 
reflect the complexity of the cases referred to our ter-
tiary centre but also the focus on preserving function 
and quality of life. Furthermore, we found that 8 of the 32 
patients (25%) had to stop tamoxifen due to side effects, 
which is higher than the previously reported rate of 10% 
[45] and remarkable given the, for this condition, rela-
tively low dose of tamoxifen prescribed in our patients 
[29, 46].
In our series 18 of the 32 patients (56%) had an increase 
in tumour size and among these, 28% were defined as 
disease progression by RECIST 1.1. This is in keeping 
with the rates of disease progression stated in a system-
atic review [18]. However, our stable disease and partial 
response rates of 69 and 3% respectively, do not correlate 
with the 18 and 58% rates previously quoted, raising the 
possibility of an overestimation in the reported efficacy of 
tamoxifen in AF. Importantly, 31% of patients did report 
symptomatic benefit, although the positive contribu-
tion of NSAIDs cannot be excluded. Seventy-five per-
cent of cases in this series were treated with concomitant 
NSAIDs, which may have influenced the results, since 
prostaglandin blockage has been shown to provide some 
benefit in the treatment of AF [47].
Interestingly, one patient treated with a fully human 
monoclonal antibody  tumor necrosis factor inhibi-
tor (TNFi), adalimumab, used for rheumatoid arthritis 
showed a response after tamoxifen discontinuation, sug-
gesting either a possible late tamoxifen effect or a role of 
immunomodulation in AF pathogenesis and treatment.
Among the population of patients with stable disease, 
representing the most heterogeneous group, we found 
a discordance between clinical symptoms and MRI T2 
changes. This could be explained by the fact that cases 
with a slight increase/decrease in size are included within 
the category of RECIST 1.1 stable disease.
Although MRI is accepted to be the best imaging 
modality for visualising AF [38] this study suggests that 
it is less useful in demonstrating therapeutic benefit on 
tamoxifen ± NSAIDs. This study has not demonstrated a 
clear relationship between MRI features (size/signal) and 
reported symptoms. This limitation may not be restricted 
to assessment of tamoxifen effects as Sheth et  al. also 
reported that RECIST were not sensitive to clinically 
determined response in 23 patients treated with a vari-
ety of local and systemic therapies [48]. Although there 
is thought provoking evidence that FDG PET/CT gives 
some early indication of response in patients treated 
with imatinib, the risk:benefit ratio of the radiation doses 
involved must be given careful consideration particularly 
where multiple assessments for non malignant pathology 
are performed, especially in young patients [49].
Our study suggests that symptoms are arguably the 
most important indicators of response to tamoxifen 
in patients with AF. According to this observation, the 
incorporation of prospective validated pain scores and 
functional assessment tools into the evaluation of treat-
ment in this disease would give a better indication of 
therapeutic benefit. This is particularly critical for the 
design of prospective AF studies where we suggest that 
endpoints should focus on patient symptoms. However, 
some experience with MRI in patients treated on pazo-
panib indicate that MRI may be more useful in assessing 
response to other agents [25].
For those patients with previous pre-baseline images 
available for comparison, a few cases showed a decrease 
in the rate of tumour growth. However, it is difficult to 
extrapolate definitive conclusions from these data because 
the number of patients with pre-baseline images was low 
and AF is known to have such a varied natural history with 
prolonged periods of stabilisation and eventual regression 
in nearly 28% of cases in one reported series [50].
Conclusions
We showed for the first time that symptomatic benefit, 
MRI T2 signal changes and tumour size correlate poorly. 
Therefore, MRI is of limited value in assessing therapeu-
tic benefit in patients treated with tamoxifen ± NSAIDs. 
This highlights the importance of robust systems to col-
lect data on patients’ symptoms and quality of life.
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